|
Questions and Answers on USP 797
Questions and
Answers on USP 797: Answers Provided by Eric S. Kastango,
MBA, RPh, FASHP:
-
E10
Question:
Can
hazardous drugs (chemotherapy) and compounded items be
mixed in the same biological safety cabinets?
-
E10 Answer:
A facility of this type has
competing needs. Negative pressure is required for
hazardous compounding and positive pressure is needed
for non-hazardous compounding. If the BSC is a
recirculating (not vented outside of the building),
there is a chance of a build of volatile vapors and risk
of cross-contamination. If it is a total exhaust BSC
(B2) and if properly decontaminated between medications
types (hazardous drugs and nonhazardous drugs), the BSC
could be used but all CSPs should be handled as
hazardous since there may be trace amounts of hazardous
drugs on area surfaces.
(Answer provided as a courtesy
to usp797.org by Eric S. Kastango, MBA, RPh, FASHP. Please
note that usp797.org is not responsible for this answer.)
-
About Eric S. Kastango: Since its
inception, Eric S. Kastango has been at the forefront of
USP <797>. He is an elected member of the United States
Pharmacopoeia Sterile Compounding Committee (2005-2010).
Over the years, he has held multiple American Society of
Health-System Pharmacists chairmanships and committee
positions. He was responsible for creating the
“Comprehensive Sterile Compounding Compliance Gap
Analysis and Risk Assessment Tool.” In this capacity,
Mr. Kastango frequents pharmacy events as an expert
speaker, contributes to industry journals, and teaches.
Mr. Kastango received his Bachelor of Science in
Pharmacy degree from the Massachusetts College of
Pharmacy and Allied Health Sciences and a MBA from the
University of Phoenix. Since 1980, he has practiced
pharmacy in a number of practice settings (including
hospitals, community, and home care) in a number of
different of roles, including the Corporate Vice
President of Pharmacy Services for Coram Healthcare
Corporation, which has 72 pharmacies in 44 states. He
has also managed a FDA-registered cGMP manufacturing
operation for Baxter Healthcare Corporation, and has
made over 100 presentations on a variety of pharmacy
practice topics. Mr. Kastango is the President and CEO
of Clinical IQ, and can be reached as follows:
Mr. Eric
S. Kastango – President and CEO
Clinical IQ, LLC
184 Columbia Turnpike, #282
Florham Park, NJ 07932
Tel: (973) 765-9393
---
www.clinicaliq.com
|